Clarity Pharmaceuticals (ASX:CU6) said results from a phase 2 diagnostic imaging study in patients with known or suspected neuroendocrine tumors showed that lesion detection by copper-64-Sartate outperformed Gallium-68-Dotatate, according to a Thursday Australian bourse filing.
The trial assessed the performance of the firm's Sartate imaging product as a potential new method to diagnose and manage neuroendocrine tumors.
Copper-64-Sartate detected 393 to 488 lesions, while Gallium-68-Dotatate identified 186 to 265 lesions.
Out of all the lesions identified, 230 to 251 of them were deemed to be discordant between copper-64-Sartate and Gallium-68-Dotatate scans, with nearly 94% of these discordant lesions detected only on the copper-64-Sartate scans.
Copper-64-Sartate was deemed safe and well tolerated, the filing said. The firm will start the next steps to conduct a registrational phase three study of copper-64-Sartate in neuroendocrine tumors with the US Food and Drug Administration's guidance.
The company recruited 45 participants with gastroenteropancreatic neuroendocrine tumors across four sites in Australia, comparing the diagnostic performance of copper-64-Sartate positron emission tomography (PET) at an average of four hours and around 20 hours post-administration to Gallium-68-Dotatate PET.
The firm's shares rose nearly 3% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.